Investors sold shares of Amgen Inc. (NASDAQ:AMGN) on strength during trading hours on Monday. $95.80 million flowed into the stock on the tick-up and $120.11 million flowed out of the stock on the tick-down, for a money net flow of $24.31 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $0.89 for the day and closed at $166.56

A number of equities analysts recently issued reports on the stock. Robert W. Baird reaffirmed a “neutral” rating and set a $157.00 target price on shares of Amgen in a research report on Friday, July 15th. BMO Capital Markets reissued a “buy” rating and issued a $186.00 price target on shares of Amgen in a report on Tuesday, July 12th. Jefferies Group reissued a “buy” rating and issued a $187.00 price target on shares of Amgen in a report on Wednesday, July 13th. Bank of America Corp. reissued a “hold” rating and issued a $182.00 price target on shares of Amgen in a report on Wednesday, July 13th. Finally, Vetr lowered shares of Amgen from a “buy” rating to a “hold” rating and set a $167.71 price target on the stock. in a report on Monday, April 18th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $181.19.

The firm has a market capitalization of $125.12 billion and a price-to-earnings ratio of 17.63. The stock has a 50 day moving average price of $156.24 and a 200-day moving average price of $153.01.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 28th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.30. During the same quarter in the prior year, the company earned $2.48 earnings per share. The business earned $5.53 billion during the quarter, compared to the consensus estimate of $5.32 billion. Amgen’s revenue was up 9.8% compared to the same quarter last year. Equities analysts anticipate that Amgen Inc. will post $11.17 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th will be given a dividend of $1.00 per share. The ex-dividend date is Monday, August 15th. This represents a $4.00 annualized dividend and a dividend yield of 2.40%.

In other news, Director David Baltimore sold 3,312 shares of the stock in a transaction dated Friday, April 29th. The stock was sold at an average price of $157.21, for a total transaction of $520,679.52. Following the transaction, the director now directly owns 32,350 shares in the company, valued at approximately $5,085,743.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sean E. Harper sold 21,875 shares of the stock in a transaction dated Friday, April 29th. The shares were sold at an average price of $157.99, for a total value of $3,456,031.25. Following the transaction, the executive vice president now owns 42,248 shares in the company, valued at $6,674,761.52. The disclosure for this sale can be found here.

A number of institutional investors recently bought and sold shares of AMGN. IFC Holdings Incorporated FL raised its position in Amgen by 3.0% in the fourth quarter. IFC Holdings Incorporated FL now owns 10,045 shares of the medical research company’s stock valued at $1,625,000 after buying an additional 291 shares during the last quarter. Henderson Group PLC raised its position in Amgen by 78.5% in the fourth quarter. Henderson Group PLC now owns 172,301 shares of the medical research company’s stock valued at $27,966,000 after buying an additional 75,783 shares during the last quarter. Toron Capital Markets Inc. raised its position in Amgen by 4.9% in the fourth quarter. Toron Capital Markets Inc. now owns 55,220 shares of the medical research company’s stock valued at $8,964,000 after buying an additional 2,577 shares during the last quarter. Wesbanco Bank Inc. raised its position in Amgen by 0.3% in the fourth quarter. Wesbanco Bank Inc. now owns 92,682 shares of the medical research company’s stock valued at $15,045,000 after buying an additional 254 shares during the last quarter. Finally, Busey Trust CO raised its position in Amgen by 1.9% in the fourth quarter. Busey Trust CO now owns 53,516 shares of the medical research company’s stock valued at $8,687,000 after buying an additional 1,016 shares during the last quarter.

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.